.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Baxter
Cantor Fitzgerald
Harvard Business School
Healthtrust
QuintilesIMS
McKinsey
Daiichi Sankyo
Julphar
Cerilliant

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
Inventor(s): Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA), Wilson; Troy Edward (San Marino, CA), Li; Liansheng (San Diego, CA), Chan; Katrina (Fremont, CA), Rommel; Christian (La Jolla, CA)
Assignee: Intellikine LLC (La Jolla, CA)
Application Number:14/884,612
Patent Claims:1. A method of treating a disease or disorder for therapeutic benefit in a subject having the disease or disorder, comprising administering to the subject an effective amount of a compound of Formula I-1: ##STR00721## or a pharmaceutically acceptable salt thereof, wherein B is a moiety of Formula II: ##STR00722## wherein W.sub.c is aryl, heteroaryl, heterocycloalkyl, or cycloalkyl, and q is an integer of 0, 1, 2, 3, or 4; X is absent or --(CH(R.sup.9)).sub.z--, and z is an integer of 1; Y is absent or --N(R.sup.9)--; W.sub.d is ##STR00723## R.sup.a' is hydrogen, halo, phosphate, urea, carbonate, unsubstituted or substituted amino, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heteroalkyl, or unsubstituted or substituted heterocycloalkyl; R.sup.1 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, amido, alkoxycarbonyl, sulfonamido, halo, cyano, or nitro; each instance of R.sup.2 is independently alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heteroarylalkyl, alkoxy, amino, halo, cyano, hydroxy, or nitro; R.sup.3 is hydrogen, alkyl, or halo; each R.sup.9 is independently hydrogen, alkyl, or heterocycloalkyl; and R.sup.12 is H, unsubstituted or substituted alkyl, cyano, unsubstituted or substituted alkynyl, unsubstituted or substituted alkenyl, halo, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted amino, carboxylic acid, unsubstituted or substituted alkoxycarbonyl, unsubstituted or substituted amido, unsubstituted or substituted acyl, or unsubstituted or substituted sulfonamido; wherein the disease or disorder is leukemia, lymphoma, lupus, or arthritis.

2. The method of claim 1, wherein the compound of Formula I-1 is selected from: ##STR00724##

3. The method of claim 1, wherein W.sub.d is selected from: ##STR00725##

4. The method of claim 1, wherein --X--Y--W.sub.d is selected from: ##STR00726## ##STR00727##

5. The method of claim 1, wherein R.sup.12 is selected from hydrogen, cyano, halo, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, and unsubstituted or substituted alkenyl.

6. The method of claim 1, wherein R.sup.12 is selected from unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocycloalkyl, and unsubstituted or substituted cycloalkyl.

7. The method of claim 1, wherein R.sup.12 is selected from unsubstituted or substituted amido, carboxylic acid, unsubstituted or substituted alkoxycarbonyl, unsubstituted or substituted acyl, and unsubstituted or substituted sulfonamido.

8. The method of claim 1, wherein R.sup.3 is alkyl.

9. The method of claim 8, wherein R.sup.3 is methyl.

10. The method of claim 1, wherein R.sup.3 is halo.

11. The method of claim 10, wherein R.sup.3 is chloro.

12. The method of claim 1, wherein the compound is: ##STR00728## ##STR00729## ##STR00730## or a pharmaceutically acceptable salt thereof.

13. The method of claim 1, wherein the compound is: ##STR00731## ##STR00732## ##STR00733## or a pharmaceutically acceptable salt thereof.

14. The method of claim 1, wherein the compound is: ##STR00734## ##STR00735## or a pharmaceutically acceptable salt thereof.

15. The method of claim 1, wherein the compound is: ##STR00736## ##STR00737## or a pharmaceutically acceptable salt thereof.

16. The method of claim 1, wherein the disease or disorder is leukemia or lymphoma.

17. The method of claim 16, wherein the disease or disorder is acute lymphocytic leukemia, hairy cell leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), or chronic neutrophilic leukemia (CNL).

18. The method of claim 16, wherein the disease or disorder is AIDS-related lymphoma, Hodgkin lymphoma, or non-Hodgkin lymphomas.

19. The method of claim 1, wherein the disease or disorder is lupus or arthritis.

20. The method of claim 1, further comprising administering radiation therapy or one or more therapeutic agents.

21. The method of claim 16, wherein the disease or disorder is B-lineage acute lymphoblastic leukemia (B-ALL), T-lineage acute lymphoblastic leukemia (T-ALL), prolymphocytic leukemia (PLL), large granular lymphocytic leukemia (LGF), diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, small non-cleaved cell lymphoma, human lymphotropic virus-type 1 (HTLV-1) leukemia/lymphoma, peripheral T cell lymphomas (PTCL), follicular lymphoma, mantle cell lymphoma, or Waldenstrom's macroglobulinemia.

22. The method of claim 16, wherein the disease or disorder is T-cell leukemia, adult T-cell lymphoma, or cutaneous T-cell lymphoma (CTCL).

23. The method of claim 20, wherein the therapeutic agent is an anti CD20 antibody.

24. The method of claim 20, wherein the therapeutic agent is rituximab, fludarabine, cyclophosphamide, bortezomib, gemcitabine, or dexamethasone, or a mixture thereof.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe Intellikine LLC (La Jolla, CA) Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA), Wilson; Troy Edward (San Marino, CA), Li; Liansheng (San Diego, CA), Chan; Katrina (Fremont, CA), Rommel; Christian (La Jolla, CA) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2009204483Jul 16, 2009
Australia2009204483Mar 13, 2014
Australia2009204487Apr 17, 2014
Australia2009204487Jul 16, 2009
Australia2009204487Oct 16, 2014
Australia2010274075Feb 09, 2012
Australia2010274075Jan 22, 2015
BrazilPI0906473Jul 14, 2015
BrazilPI0906474Jul 14, 2015
Canada2711446Dec 06, 2016
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
US Army
Chinese Patent Office
Queensland Health
McKinsey
Healthtrust
Cipla
Chubb
Argus Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot
Parse error: syntax error, unexpected '"', // point' (T_CONSTANT_ENCAPSED_STRING), expecting ',' or ';' in /home/thinkbio/public_html/drugpatentwatch/inc/bs-js.php on line 17